Parabilis Medicines, Inc. (PBLS)
Technology · NasdaqGS · US
Fundamentals
Valuation and ratings
Parabilis Medicines, Inc. trades at USD29.06. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
PBLS passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
The full research page for PBLS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.